IOL Chemicals and Pharmaceuticals net profit rises 43.5% to Rs.107.2 crore in 9M FY24

▴ IOLCP
The company is the World’s largest producer of Ibuprofen with an installed capacity of 12,000 TPA and having backward integrated manufacturing facility. The Company has DSIR-approved R&D which is fully equipped to validate existing processes.

     Total income for 9M FY24 stood at Rs.1,651 crore against Rs.1,647 crore YoY

  • EBITDA for 9M FY24 at Rs.204.0 crore up by 38.4% YoY
  • Net profit for 9M FY24 at Rs.107.2 crore up by 43.5% YoY
  • Received CEP Certificate for Losartan Potassium issued by EDQM which will enable higher export to European market
  • The Board declared an Interim Dividend of Rs.5/- Share

 

08th February, 2024, New Delhi:

IOL Chemicals and Pharmaceuticals Ltd, a leading manufacturer of pharmaceutical APIs and speciality chemicals, announced its financial results for the third quarter and nine months ended December 31, 2023.

 

Consolidated Q3 & 9M FY24 Financial Highlights                                          

                                                                                                                                                  (Rs. in Crore)

Particulars

Q3 FY24

Q3 FY23

% YoY

9M FY24

9M FY23

% YoY

Total Income

528.8

530.1

-0.2%

1651.4

1,646.8

0.3%

EBITDA

52.9

49.7

6.4%

204.0

147.6

38.2%

EBITDA Margin (%)

10.0%

9.4%

60 bps

12.3%

8.9%

340 bps

PAT

23.2

24.2

-4.1%

107.2

74.7

43.5%

PAT Margin (%)

4.4%

4.6%

-20 bps

6.5%

4.5%

200 bps

 

Commenting on the performance, Mr Vikas Gupta, Joint Managing Director said, “Despite sectoral headwinds, the Company has shown resilience in its financial performance during nine months period. The company’s EBITDA margin has improved led by declining input cost. We recently received CEP certificate approval for Losartan Potassium by EDQM providing us an opportunity to further expand our exports into the regulated markets. We are continuously focusing on improving operational efficiencies further through backward integration.”


 

 

About IOL Chemicals and Pharmaceuticals Limited (IOLCP)

Established in 1986 and listed on the National Stock Exchange of India Ltd (Code: IOLCP) and BSE Ltd (Code: 524164), IOL Chemicals and Pharma is one of the leading pharmaceutical (APIs) Companies and a significant player in the specialty chemicals space with world-class facilities. IOLCP has a wide presence across major therapeutic categories like Pain Management, anti-convulsants, anti-diabetes, anti-cholesterol and anti-platelets.

 

The Company’s product portfolio includes APIs; Ibuprofen, Metformin, Fenofibrate, Clopidogrel, Lamotrigine, Pantoprazole, Paracetamol and specialty chemicals such as Ethyl Acetate, Iso Butyl Benzene, Mono Chloro Acetic Acid and Acetyl Chloride.

 

The company is the World’s largest producer of Ibuprofen with an installed capacity of 12,000 TPA and having backward integrated manufacturing facility. The Company has DSIR-approved R&D which is fully equipped to validate existing processes.

 

The Central and State Government approved Effluent Treatment Plant (ETP) had been set up with Zero Liquid Discharge (ZLD) system along with a 17 MW captive Co-Generation plant for self-reliance. The Company is ISO 9001:2015, 14001:2015 and BS OHSAS 18001:2007 certified.

 

IOLCP's overseas customers are spread out across several countries including the UK, Belgium, Hungry, Spain, Germany, Italy, Netherlands, Switzerland, Poland, Ireland, USA, Peru, Brazil, Argentina, Colombia, Indonesia, South Korea, Thailand, Bangladesh, Turkey, U.A.E., China, Hong Kong, Egypt etc. Products are sold primarily to Branded Generic formulators both in India & Overseas.

Tags : #

About the Author


Team Medicircle

Related Stories

Loading Please wait...

-Advertisements-




Trending Now

New Milestone: First Cryopreserved Stem Cell Donation Helps Blood Cancer Patient December 13, 2024
Everest Medicines Announces the First Prescription of VELSIPITY(R) Issued in MacauDecember 13, 2024
Plastic Pollution Goes Personal: Microplastics Found in Human BloodDecember 12, 2024
The Fat-Fuelled Weapon Against Cancer: How the Keto Lifestyle is Redefining Cancer TherapyDecember 12, 2024
Gene Therapy in India: How Indian Scientists Redefined Hemophilia TreatmentDecember 12, 2024
Empowering India’s Workforce: FinX Raises $6M from Elevar Equity to revolutionise employability in the BFSI IndustryDecember 12, 2024
India’s Win Over Malaria: A Global Health Victory in ProgressDecember 11, 2024
TB-Free India by 2025: Bold Vision or Achievable Reality?December 11, 2024
Aakash Healthcare Supports the 14th Special Athletic Meet for Children with Special NeedsDecember 11, 2024
The University of Manchester invites applications for an MSc in International Disaster ManagementDecember 10, 2024
Preventing Mother-to-Child HIV Transmission: Strategies and ImportanceDecember 10, 2024
USIBC Signs MOU with Government of Telangana, Hosts AI and GCC Industry RoundtableDecember 10, 2024
CarDekho Group’s New Auto Segment’s Shift in Fuel Preferences Report: Electric Vehicles (EVs) Lead the Chart with 26% YoY Traffic Increase December 10, 2024
India’s leading eCommerce enablement platform Shiprocket appoints industry veteran Vivek Sharma as VP of International ShippingDecember 10, 2024
Failure to find all TB cases defeats us in #endTB effortsDecember 10, 2024
Fear of Missing Out or Fear of Missing Connections: How FOMO Reflects Our Need for BelongingDecember 10, 2024
Rewriting Elderly Care: Rs 5 Lakh Healthcare for India’s Elderly Through Ayushman Vay Vandana CardDecember 10, 2024
ISB DLabs in collaboration with CitiusTech launches ‘I-HEAL @ ISB 3.0’: Accelerating Digital Healthcare Innovation in IndiaDecember 10, 2024
Aditya Roy Kapur unveils PartySmart Gummies for hangover preventionDecember 10, 2024
Sightsavers India and Alcon India Inaugurate Block Resource Centre aimed to Empower Children with Visual Impairment in BankuraDecember 10, 2024